Protagonist Therapeutics's - PTGX market analysis on 27th September 2020

Transaction Date	Recipient	Shares	Type	Price	Value
11th August 2020	Chaitan Phd Khosla	2,499	Open or private sale	$17.19	$42,952.06
11th August 2020	Chaitan Phd Khosla	2,499	Exercise of derivative	$1.89	$4,723.11
23rd June 2020	Bryan Giraudo	2,000	Open or private purchase	$12.96	$25,922.40
29th April 2020	Dinesh V Ph D Patel	2,000	Bona fide gift	$0.00
20th March 2020	Dinesh V Ph D Patel	10,000	Exercise of derivative	$1.89	$18,900.00
12th March 2020	Dinesh V Ph D Patel	18,344	Exercise of derivative	$1.16	$21,279.04
12th March 2020	Harold E Selick	12,000	Open or private purchase	$6.70	$80,400.00
14th February 2020	Bryan Giraudo	46,500	Grant/award etc.	$0.00
3rd December 2019	Dinesh V Ph D Patel	10,000	Open or private purchase	$5.55	$55,500.00
3rd December 2019	Dinesh V Ph D Patel	20,000	Open or private purchase	$5.65	$113,000.00

Protagonist Therapeutics

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm's initial lead product candidates are being developed for moderate-to-severe ulcerative colitis and Crohn's disease.

Ticker: PTGX

Sector: Healthcare

Industry: Biotechnology

SEC Central Index Key (CIK): 1377121

Employees: 64

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis